California News Reporter

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2023 report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including Diffuse Large B-Cell Lymphoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Diffuse Large B-cell Lymphoma Emerging drugs, the Diffuse Large B-cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Diffuse Large B-cell Lymphoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Diffuse Large B-cell Lymphoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Diffuse Large B-cell Lymphoma clinical trials studies, Diffuse Large B-cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report

 

• DelveInsight’s Diffuse Large B-Cell Lymphoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.

 

• The leading Diffuse Large B-Cell Lymphoma Companies are working such as Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, and others.

 

• Promising Diffuse Large B-Cell Lymphoma Pipeline therapies such as Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, DA-EPOCH-R, Lenalidomide, VELCADE, Cyclophosphamide, HS006+CHOP, and others.

 

• The Diffuse Large B-Cell Lymphoma Companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

 

Request a sample and discover the recent breakthroughs happening in the Diffuse Large B-cell Lymphoma Pipeline landscape @ Diffuse Large B-cell Lymphoma Pipeline Outlook Report

 

Diffuse Large B-cell Lymphoma Overview

 

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females.

 

Recent Developmental Activities in the Diffuse Large B-Cell Lymphoma Pipeline

 

• Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

 

• Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.

 

• Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

 

• AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

 

• Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

  

For further information, refer to the detailed Diffuse Large B-cell Lymphoma Drugs Launch, Diffuse Large B-cell Lymphoma Developmental Activities, and Diffuse Large B-cell Lymphoma News, click here for Diffuse Large B-cell Lymphoma Ongoing Clinical Trial Analysis

 

Diffuse Large B-cell Lymphoma Emerging Drugs Profile

 

• Epcoritamab: Genmab

Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

 

• Glofitamab: Roche

Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.

 

• Acalabrutinib: Acerta Pharma

Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

 

• AUTO 3: Autolus

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

 

• Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.

 

Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.

 

Find out more about the Diffuse Large B-cell Lymphoma Pipeline Segmentation, Therapeutics Assessment, and Diffuse Large B-cell Lymphoma Emerging Drugs @ Diffuse Large B-cell Lymphoma Treatment Landscape

 

Scope of the Diffuse Large B-cell Lymphoma Pipeline Report

 

• Coverage- Global

 

• Diffuse Large B-Cell Lymphoma Companies- Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis, Inc., Bayer, Kartos Therapeutics, Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio, Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio, Inc., Telios Pharma, Inc., Sorrento Therapeutics, Inc., Curocell Inc., TG Therapeutics, Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs, Inc., MEI Pharma, Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma, Inc, Newave Pharmaceutical Inc, Eden BioCell Ltd., Adicet Bio, Inc, VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics, Inc., Prelude Therapeutics, Xencor, and others.

 

• Diffuse Large B-Cell Lymphoma Pipeline Therapies- Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, DA-EPOCH-R, Lenalidomide, VELCADE, Cyclophosphamide, HS006+CHOP, and others.

 

• Diffuse Large B-Cell Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Diffuse Large B-cell Lymphoma Pipeline Companies and Therapies, click here @ Diffuse Large B-cell Lymphoma Unmet Needs and Analyst Views

 

Table of Content

 

1. Introduction
2. Executive Summary
3. Diffuse Large B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diffuse Large B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Diffuse Large B-Cell Lymphoma Collaboration Deals
9. Late Stage Products (Phase III)
10. Epcoritamab: Genmab
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Abexinostat: Xynomic Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. AUTO 3: Autolus
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Diffuse Large B-Cell Lymphoma Key Companies
20. Diffuse Large B-Cell Lymphoma Key Products
21. Diffuse Large B-Cell Lymphoma- Unmet Needs
22. Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
23. Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
24. Diffuse Large B-Cell Lymphoma Analyst Views
25. Diffuse Large B-Cell Lymphoma Key Companies
26. Appendix

 

Got Queries? Find out the related information on Diffuse Large B-cell Lymphoma Mergers and acquisitions, Diffuse Large B-cell Lymphoma Licensing Activities @ Diffuse Large B-cell Lymphoma Recent Trends, and Future Perspectives 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/